Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $62.78 USD
Change Today -0.30 / -0.48%
Volume 1.1M
STJ On Other Exchanges
New York
As of 8:04 PM 11/24/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

One St. Jude Medical Drive

St. Paul, MN 55117

United States

Phone: 651-756-2000

Fax: 651-756-3301

efibrillation leads. The company’s ICD lead offerings include the Optisure (FDA approval in April 2014), Durata SJ4 (FDA approval in 2009), and Durata high-voltage leads (FDA approval in 2007). All the company’s ICD leads feature its exclusive Optim insulation material that combines the durability of polyurethane and the softness of silicone. The company has Optim insulation available in all of the company’s lead segments and have phased out it solder silicone insulated leads. The company’s portfolio of CRT leads includes the Quartet low voltage (LV) lead (FDA approval and European CE Mark approval), as well as the smaller diameter lead, QuickFlex µ (micro) LV lead (FDA approval and European CE Mark approval). Both the Quartet and QuickFlex µ are Optim insulated leads. The Quartet lead features four electrodes spaced approximately 4.7 centimeters, enabling approximately 10 pacing configurations. Multiple pacing configurations allow the physician to implant the lead in the most stable position without sacrificing electrical performance. It also provides the physician more alternatives to pace closer to the base of the left ventricle. The quadripolar pacing electrodes also provide physicians more options to optimize CRT performance, such as pacing around scar tissue in the heart. For LV lead implantation, the company received FDA and European CE Mark approval in 2013 for improved versions of its CPS Aim SL and CPS Direct SL II slittable LV lead delivery tools designed to offer safe and efficient implantation procedures and improved compatibility with the company’s Quartet LV lead. It also provides additional tools for the placement of LV leads, including the CPS Luminary, CPS Duo, CPS Courier guidewires and the CPS Venture wire control catheter. Pacemaker Systems The company’s pacemakers treat patients with hearts that beat too slowly, a condition known as bradycardia. Similar to ICDs and CRT-Ds, pacemakers are typically implanted underneath the collarbone, monitor heart rate, and when necessary, deliver low-voltage electrical impulses to stimulate an appropriate heartbeat. In 2013, the company received European CE Mark approval for the first leadless pacemaker system that it acquired through its acquisition of Nanostim. Unlike conventional pacemakers that require an invasive surgery, the Nanostim leadless pacemaker is designed to be implanted directly into the heart through a less invasive procedure. The device is delivered using a steerable catheter through the femoral vein, eliminating the need to surgically create a pocket for the pacemaker and also eliminating the need for insulated wires (leads) that have historically been recognized as the most vulnerable component of pacing systems. The company’s pacemaker portfolio also includes the Assurity and Endurity traditional pacemakers and Allure CRT pacemakers (FDA approval in April 2014 and European CE Mark approval in 2013). Allure Quadra brings the quadripolar lead technology to the pacemaker market (FDA approval in March 2014 and European CE Mark approval in 2013). Quadripolar leads allow for increased implant efficiencies, which clinical data indicates could result in fewer surgical revisions. The Allure family of devices also offers improved HF diagnostics, including CorVue Impedance Monitoring, for improved patient management. In December 2014, the company announced European CE Mark approval of its next-generation quadripolar CRT pacemaker, the Quadra Allure MP CRT-P (cardiac resynchronization therapy pacemaker) device, which features MultiPoint Pacing technology. The Assurity and Endurity family of pacemakers further improves the company’s pacemaker portfolio with smaller size and improved battery longevity. These new devices complement the company’s existing Accent MRI pacemaker family (introduced in Europe and Japan). The Accent MRI system features the Accent MRI pacemaker devices and the Tendril MRI lead with added filtering capabilities for safety during an MRI scan. In combination, the Accent MRI pacemaker and the Tendril MRI lead allow for a full-body MRI scan without zone restrictions. Additionally, the system includes the MRI activator to


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STJ:US $62.78 USD -0.30

STJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $186.24 USD -1.02
Olympus Corp ¥4,900 JPY -30.00
Smith & Nephew PLC 1,120 GBp +13.00
Terumo Corp ¥3,965 JPY -60.00
Zimmer Biomet Holdings Inc $101.92 USD -0.93
View Industry Companies

Industry Analysis


Industry Average

Valuation STJ Industry Range
Price/Earnings 17.9x
Price/Sales 3.2x
Price/Book 4.5x
Price/Cash Flow 16.1x
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ST JUDE MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at